Ionis Pharmaceuticals, Inc. (LON:0JDI)
London
· Delayed Price · Currency is GBP · Price in USD 28.98
-0.09 (-0.30%)
At close: Apr 25, 2025
Ionis Pharmaceuticals Revenue
In the year 2024, Ionis Pharmaceuticals had annual revenue of $705.14M USD, down -10.48%. Ionis Pharmaceuticals had revenue of $226.58M in the quarter ending December 31, 2024, a decrease of -30.18%.
Revenue
$705.14M
Revenue Growth
-10.48%
P/S Ratio
6.30
Revenue / Employee
$659.62K
Employees
1,069
Market Cap
3.55B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Oxford Nanopore Technologies | 183.19M |
Ionis Pharmaceuticals News
- 5 days ago - Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade) - Seeking Alpha
- 20 days ago - This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
- 24 days ago - Ionis to host expert panel discussion on sHTG - Business Wire
- 27 days ago - Ionis to present at upcoming investor conferences - Business Wire
- 4 weeks ago - Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - Business Wire
- 6 weeks ago - Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - Benzinga
- 6 weeks ago - Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - Seeking Alpha
- 6 weeks ago - Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera - Business Wire